Fig. 1 | Cellular & Molecular Immunology

Fig. 1

From: New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

Fig. 1

A recombinant vaccine targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike can induce a protective immune response. The recombinant RBD protein was expressed in insect cells using the Bac-to-Bac system and Alum-precipitated for vaccine formulation. After the vaccination of the nonhuman primate monkeys with the RBD vaccine, serum antibodies that could bind the RBD and neutralize viral infection were effectively induced, providing the rationale for the development of a protective vaccine through the induction of antibodies against the RBD

Back to article page